Asbestos exposure, pleural mesothelioma, and serum osteopontin levels.
BACKGROUND
We investigated the presence of osteopontin in pleural mesothelioma and determined serum osteopontin levels in three populations: subjects without cancer who were exposed to asbestos, subjects without cancer who were not exposed to asbestos, and patients with pleural mesothelioma who were exposed to asbestos.


METHODS
A group of 69 subjects with asbestos-related nonmalignant pulmonary disease were compared with 45 subjects without exposure to asbestos and 76 patients with surgically staged pleural mesothelioma. Tumor tissue was examined for osteopontin by immunohistochemical analysis, and serum osteopontin levels were measured by an enzyme-linked immunosorbent assay.


RESULTS
There were no significant differences in mean (+/-SE) serum osteopontin levels between age-matched subjects with exposure to asbestos and subjects without exposure to asbestos (30+/-3 ng per milliliter and 20+/-4 ng per milliliter, respectively; P=0.06). In the group with exposure to asbestos, elevated serum osteopontin levels were associated with pulmonary plaques and fibrosis (56+/-13 ng per milliliter) but not with normal radiographic findings (21+/-5 ng per milliliter), plaques alone (23+/-3 ng per milliliter), or fibrosis alone (32+/-7 ng per milliliter) (P=0.004). Serum osteopontin levels were significantly higher in the group with pleural mesothelioma than in the group with exposure to asbestos (133+/-10 ng per milliliter vs. 30+/-3 ng per milliliter, P<0.001). Immunohistochemical analysis revealed osteopontin staining of the tumor cells in 36 of 38 samples of pleural mesothelioma. An analysis of serum osteopontin levels comparing the receiver-operating-characteristic curve in the group exposed to asbestos with that of the group with mesothelioma had a sensitivity of 77.6 percent and a specificity of 85.5 percent at a cutoff value of 48.3 ng of osteopontin per milliliter. Subgroup analysis comparing patients with stage I mesothelioma with subjects with exposure to asbestos revealed a sensitivity of 84.6 percent and a specificity of 88.4 percent at a cutoff value of 62.4 ng of osteopontin per milliliter.


CONCLUSIONS
Serum osteopontin levels can be used to distinguish persons with exposure to asbestos who do not have cancer from those with exposure to asbestos who have pleural mesothelioma.
Pass
Harvey I
HI
Department of Surgery, Wayne State University, Karmanos Cancer Institute, John A. Dingell Veterans Hospital, Detroit, Mich, USA. harvey.pass@med.nyu.edu
Lott
Dan
D
Lonardo
Fulvio
F
Harbut
Michael
M
Liu
Zhandong
Z
Tang
Naimei
N
Carbone
Michele
M
Webb
Craig
C
Wali
Anil
A
D000368:Aged; D001194:Asbestos / Q000009:adverse effects*; D001195:Asbestosis / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D005260:Female; D006801:Humans; D008297:Male; D008654:Mesothelioma / Q000097:blood* / Q000175:diagnosis / Q000401:mortality / Q000601:surgery; D008875:Middle Aged; D009367:Neoplasm Staging; D016273:Occupational Exposure; D053495:Osteopontin; D010997:Pleural Neoplasms / Q000097:blood* / Q000175:diagnosis / Q000401:mortality / Q000601:surgery; D012372:ROC Curve; D012044:Regression Analysis; D012795:Sialoglycoproteins / Q000032:analysis / Q000097:blood*; D016019:Survival Analysis
D015415:Biomarkers; C506895:SPP1 protein, human; D012795:Sialoglycoproteins; D053495:Osteopontin; D001194:Asbestos